.png){kind=icon}
.png){kind=icon}
Return
Safety, immunogenicity, and effectiveness of the MAV/06 varicella vaccine: A comprehensive review of a new strain vaccine
.png){kind=icon}
OA
AI
Y
Younchul Shin*H
Hyunji RyuG
Gwanglok KimS
Shinha YangJ
Jaewoo LeeB
BongKyoo Choi* DOI：10.1080/21645515.2026.2627097.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Most of licensed varicella vaccines are based on the Oka strain, while MAV/06 strain vaccines were exclusively developed by GC Biopharma Corp. in South Korea. This paper aims to summarize and present more than 30 y of accumulated evidence from about 40 unpublished and published studies on safety, immunogenicity, and effectiveness of MAV/06 vaccines. The safety of MAV/06 vaccines has been confirmed through various clinical trials and post-marketing studies. Outstanding humoral and cell-mediated immunogenicity of the MAV/06 vaccines has been demonstrated in diverse clinical trials and real-world studies. For example, a seroconversion rate of the MAV/06 vaccine (BARYCELA inj.) was close to 100%. Moreover, several after-approval epidemiological studies in Korean and Filipino children have supported the effectiveness of MAV/06 vaccines, although it remains to be further confirmed in future studies. In terms of safety, immunogenicity, and effectiveness, MAV/06 strain varicella vaccines are comparable to Oka strain vaccines.
Keywords:
Varicella vaccines
MAV/06 strain
cost-effective
safety
immunogenicity
effectiveness
Journal
H
IF:
0
Papers:
6
Citations:
0
Organization
Cited Papers